Spinal Muscular Atrophy (SMA) Treatment with SPINRAZA (Nusinersen) Plan | Beijing Jingdu Children's Hospital, China

Spinal Muscular Atrophy (SMA) is a life-threatening, rare genetic disease. Beijing Jingdu Children's Hospital (JCI-accredited Level III), focusing on SMA precision treatment, offers a standardized system centered on nusinersen intrathecal injection. Backed by a multidisciplinary team (pediatrics, neurology, anesthesiology, rehabilitation), it provides painless treatment, the world's lowest cost, and 1-day hospitalization, significantly reducing child suffering and family burden. Multidisciplinary Team for Safe & Precise Treatment: The exclusive SMA MDT team provides full-process personalized care: neurologists determine typing and dosages; pediatricians ensure safety; anesthesiologists support painless injection; rehabilitation specialists optimize recovery. Collaboration with top institutions guarantees advanced treatment. Painless Intrathecal Injection: Custom sedation plans and advanced painless technologies allow children to undergo treatment in sleep, avoiding pain and psychological trauma from traditional puncture. Humanistic care enhances compliance. World's Lowest Cost: Supported by medical insurance and refined cost control, Nusinersen treatment costs are the lowest globally. Transparent pricing, insurance reimbursement, and rare disease assistance reduce family burden. 1-Day Efficient Hospitalization: Optimized process enables "same-day admission and discharge": preoperative exams completed in advance; painless injection done on admission day; discharge after uneventful monitoring, minimizing life disruption. JCI Quality Control: JCI-accredited, the hospital enforces strict drug safety checks and ultrasound-guided injections. An exclusive follow-up system ensures sustained treatment effects via online-offline guidance.